Dr Jonathan OLIVIER
@jo-uro.bsky.social
MD PhD MCU-PH Urologist Robot-Laser surgery &UroOnco @CHU_Lille. Coordinateur relations internationales @medecine_Ulille. Member @EAU_YAUProstate
Thrilled to share our new @BJUIjournal study!
📊 Quantifying Gleason pattern 4 via MRI & targeted biopsy predicts prostate cancer metastasis better than standard Gleason grading & risk scores.
Precision matters in risk stratification.
🔗 doi.org/10.1111/bju.... @vickersbiostats.bsky.social
📊 Quantifying Gleason pattern 4 via MRI & targeted biopsy predicts prostate cancer metastasis better than standard Gleason grading & risk scores.
Precision matters in risk stratification.
🔗 doi.org/10.1111/bju.... @vickersbiostats.bsky.social
Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome
Objectives To determine if quantifying Gleason pattern 4 (GP4) is superior to Grade Group (GG) in predicting any and distant metastatic recurrence after radical prostatectomy (RP) for prostate cance...
doi.org
August 27, 2025 at 8:49 PM
Thrilled to share our new @BJUIjournal study!
📊 Quantifying Gleason pattern 4 via MRI & targeted biopsy predicts prostate cancer metastasis better than standard Gleason grading & risk scores.
Precision matters in risk stratification.
🔗 doi.org/10.1111/bju.... @vickersbiostats.bsky.social
📊 Quantifying Gleason pattern 4 via MRI & targeted biopsy predicts prostate cancer metastasis better than standard Gleason grading & risk scores.
Precision matters in risk stratification.
🔗 doi.org/10.1111/bju.... @vickersbiostats.bsky.social
Happy to share our new meta-analysis that highlights a critical finding: 16% of mCRPC cases treated with ARPIs transition to t-NEPC. Routine biopsies could improve detection of this progression.
@chulille.bsky.social @eururoloncol.bsky.social
euoncology.europeanurology.com/article/S258...
@chulille.bsky.social @eururoloncol.bsky.social
euoncology.europeanurology.com/article/S258...
Emergence of Neuroendocrine Tumors in Patients Treated with Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
Androgen receptor pathway inhibitor treatment for metastatic castration-resistant
prostate cancer (PC) can lead to the development of neuroendocrine PC (t-NEPC) in
approximately 16% of cases. This agg...
euoncology.europeanurology.com
January 19, 2025 at 9:44 PM
Happy to share our new meta-analysis that highlights a critical finding: 16% of mCRPC cases treated with ARPIs transition to t-NEPC. Routine biopsies could improve detection of this progression.
@chulille.bsky.social @eururoloncol.bsky.social
euoncology.europeanurology.com/article/S258...
@chulille.bsky.social @eururoloncol.bsky.social
euoncology.europeanurology.com/article/S258...